<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="859">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627623</url>
  </required_header>
  <id_info>
    <org_study_id>2020/ABM /COVID19/0044</org_study_id>
    <nct_id>NCT04627623</nct_id>
  </id_info>
  <brief_title>Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration</brief_title>
  <acronym>EpiSARS2</acronym>
  <official_title>Prevalence and Risk Factors of COVID-19 Infection in the Upper Silesian Agglomeration Population in 2020</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project is designed as a comprehensive population-based epidemiological study in&#xD;
      Upper-Silesian Conurbation (Poland) aiming at:&#xD;
&#xD;
        1. analysis of available data on incidence and mortality due to COVID-19 and&#xD;
&#xD;
        2. estimation of the occurrence of viral infection SARS-CoV-2 as revealed by the results of&#xD;
           serological test (ELISA: IgM, IgG), with assessment of risk factors.&#xD;
&#xD;
      The project's objectives are: to assess incidence and mortality due COVID-19 according to&#xD;
      sex, age and coexisting diseases; to determine the level of potential &quot;underdiagnosis&quot; of the&#xD;
      magnitude of COVID-19 mortality using vital statistics data for Upper-Silesian Conurbation;&#xD;
      to assess the prevalence of SARS-CoV-2 based on the level of seropositivity in Upper-Silesian&#xD;
      Conurbation; to identify host-related and environmental risk factors if the infection.&#xD;
      Analysis of existing data will include monthly records on incidence and mortality over the&#xD;
      period 01.01.2020-31.12.2020 and comparison of the findings with the monthly records of 2018&#xD;
      and 2019, for the same population. Cross-sectional epidemiological study will be located in&#xD;
      three towne (Katowice, Sosnowiec, Gliwice). In each town a representative age-stratified&#xD;
      sample of 2000 subjects will undergo questionnaire assessment and serological examination&#xD;
      performed by serological test. The project corresponds with analogous population-based&#xD;
      studies on COVID-19 in a number of countries and responds to the WHO recommendation in that&#xD;
      field.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project is designed as a comprehensive population-based epidemiological study in&#xD;
      Upper-Silesian Conurbation (Poland) aiming at:&#xD;
&#xD;
        1. analysis of available data on incidence and mortality due to COVID-19 and&#xD;
&#xD;
        2. estimation of the occurrence of viral infection SARS-CoV-2 as revealed by the results of&#xD;
           serological test (ELISA: IgM, IgG), with assessment of risk factors.&#xD;
&#xD;
      The project's objectives are: to assess incidence and mortality due COVID-19 according to&#xD;
      sex, age and coexisting diseases; to determine the level of potential &quot;underdiagnosis&quot; of the&#xD;
      magnitude of COVID-19 mortality using vital statistics data for Upper-Silesian Conurbation;&#xD;
      to assess the prevalence of SARS-CoV-2 based on the level of seropositivity in Upper-Silesian&#xD;
      Conurbation; to identify host-related and environmental risk factors if the infection.&#xD;
      Analysis of existing data will include monthly records on incidence and mortality over the&#xD;
      period 01.01.2020-31.12.2020 and comparison of the findings with the monthly records of 2018&#xD;
      and 2019, for the same population. Cross-sectional epidemiological study will be located in&#xD;
      three towne (Katowice, Sosnowiec, Gliwice). In each town a representative age-stratified&#xD;
      sample of 2000 subjects will undergo questionnaire assessment and serological examination&#xD;
      performed by serological test. The project corresponds with analogous population-based&#xD;
      studies on COVID-19 in a number of countries and responds to the WHO recommendation in that&#xD;
      field.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">April 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of prevalence of specific anti-SARS-CoV-2 IgM and IgG antibodies in general population.</measure>
    <time_frame>8 months</time_frame>
    <description>Estimation of real prevalence of elevated IgM and IgG COVID antibodies in general population will allow to estimate real number of current and past COVID infection in the population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of asymptomatic course of COVID in individuals with anti-SARS-CoV2 antibodies</measure>
    <time_frame>8 months</time_frame>
    <description>Prevalence of asymptomatic cases into seropositive population</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Covid19</condition>
  <condition>Respiratory Tract Infections</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <condition>Corona Virus Infection</condition>
  <condition>RNA Virus Infections</condition>
  <condition>Virus Disease</condition>
  <condition>Respiratory Tract Disease</condition>
  <arm_group>
    <arm_group_label>Screened arm</arm_group_label>
    <description>6000 peoples (3x2000) in all ages randomly selected from the general population of three towns (Katowice, Sosnowiec, Gliwice).&#xD;
From all invited is collected a venous blood samples (5ml) to assay IgM and IgG antibodies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IgM and IgG antibodies assay</intervention_name>
    <description>5 ml venous blood sample collection to assay IgM and IgM against COVID19</description>
    <arm_group_label>Screened arm</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5 ml venous blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Selected by random inhabitants of one of three towns (Katowice, Sosnowiec, Gliwice) with no&#xD;
        age limits.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: citizens of one of three towns (Katowice, Sosnowiec, Gliwice) with no&#xD;
        age limits&#xD;
&#xD;
        Exclusion Criteria: person who is not able to contact laboratory and obtain blood sample.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan E Zejda, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Silesia in Katowice Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grzegorz M Brozek, Prof</last_name>
    <phone>0048 693 700 184</phone>
    <email>gbrozek@sum.edu.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diagnostyka sp zoo</name>
      <address>
        <city>Katowice</city>
        <zip>40-282</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafa≈Ç Trela</last_name>
      <phone>0048 728331386</phone>
      <email>rafal.trela@diag.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Pan Y, Li X, Yang G, Fan J, Tang Y, Zhao J, Long X, Guo S, Zhao Z, Liu Y, Hu H, Xue H, Li Y. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect. 2020 Jul;81(1):e28-e32. doi: 10.1016/j.jinf.2020.03.051. Epub 2020 Apr 10.</citation>
    <PMID>32283141</PMID>
  </reference>
  <reference>
    <citation>Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, Sun R, Wang Y, Hu B, Chen W, Zhang Y, Wang J, Huang B, Lin Y, Yang J, Cai W, Wang X, Cheng J, Chen Z, Sun K, Pan W, Zhan Z, Chen L, Ye F. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Sep;92(9):1518-1524. doi: 10.1002/jmv.25727. Epub 2020 Apr 13.</citation>
    <PMID>32104917</PMID>
  </reference>
  <reference>
    <citation>Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. doi: 10.1093/cid/ciaa344.</citation>
    <PMID>32221519</PMID>
  </reference>
  <reference>
    <citation>Lee CY, Lin RTP, Renia L, Ng LFP. Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Front Immunol. 2020 Apr 24;11:879. doi: 10.3389/fimmu.2020.00879. eCollection 2020. Review.</citation>
    <PMID>32391022</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Silesia</investigator_affiliation>
    <investigator_full_name>Prof. Grzegorz Bro≈ºek, MD PhD</investigator_full_name>
    <investigator_title>Prof. Grzegorz Bro≈ºek, MD PhD</investigator_title>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Risk factors</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Mortality</keyword>
  <keyword>anti-SARS-CoV-2 antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

